Leah Kuntz

FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.

HHS targets psychiatric overprescribing; expert Joseph F. Goldberg, MD, urges careful deprescribing—stop ineffective medications and replace with evidence-based treatments.

HHS rolls out a plan to curb psychiatric overprescribing, pushing deprescribing guidance as APA and AFSP urge caution and access to care.

In the wake of the FDA fast-track of psychedelic therapies, we want to hear your clinical pearls for our May theme.

Check out the pipeline updates from April!

The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.

New US patent backs Denovo’s ANK3 biomarker guiding DB104 for treatment‑resistant depression, highlighting promising efficacy in selected patients.

Read our exclusive interview with Daniel R. Karlin, MD, MA, on the latest executive order, DT120 for the treatment of mental health disorders, and more.

Adial seeks FDA priority voucher to speed AD04 review, a biomarker-guided therapy aiming to curb heavy drinking in alcohol use disorder.

FDA expands Caplyta label to prevent schizophrenia relapse, cutting risk 63% and showing weight-neutral tolerability for sustained long-term stability.

AXS-05 for Alzheimer disease agitation nears FDA decision date.

How do estrogen, testosterone, and aromatase shape binge eating and bulimia risk? Let's explore brain biomarkers and future hormone-aware treatments.

AFSP and JED plan a 2026 merger to form the largest US suicide prevention nonprofit, uniting research, youth mental health programs, advocacy, and community support.

Two-dose oral R‑MDMA, EMP-01, cuts social anxiety symptoms and real‑world avoidance in phase 2a study, with strong responder rates and good tolerability.

Vibrance-1 phase 2 results show alixorexton improves narcolepsy type 1 severity, cognition, and fatigue for 13 weeks with good tolerability.

ASAM’s new youth SUD criteria help clinicians deliver developmentally tailored, prevention-first care with coordinated family and community supports.

A new US-based grant program seeks to create training content for health care providers who want to be able to deliver investigational COMP360 psilocybin treatment.

New ASAM youth criteria redefine SUD care with brain-stage levels, chronic monitoring, detox safety, and family-centered support.

Deep intracranial frequency stimulation 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with nonsuicidal self-injury.

A new US Department of War backed phase 2a study will test BXCL501's efficacy in easing acute stress reactions and preventing PTSD.

Early MRS data show AL001 delivers lithium effects across the brain while sparing glutamate, hinting at better tolerability than lithium carbonate.

Lipocine's oral brexanolone (LPCN 1154) for the treatment of postpartum depression failed to meet the primary endpoint in a phase 3 placebo-controlled trial.

New initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and type 2.

Explore fresh clinical insights on schizophrenia—mortality, stigma, cannabis links, lifestyle, and new treatments—and share cases for our April series.

Q1 psychiatric pipeline shifts: wins, setbacks, and standout trials in depression, schizophrenia, Alzheimer disease, and narcolepsy—what to watch next.

Check out the pipeline updates from March!

A panel of experts presented new consensus recommendations focused on the screening, diagnosis, and treatment of tardive dyskinesia among older adults in long-term care settings.

ASAM announces new youth substance use disorder criteria, promoting early intervention, family-focused care, integrated mental health, and updated levels of treatment.

LB Pharmaceuticals has initiated the pivotal phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia.